News

April 20, 2018

Remission Rates, Not Disease Origin, Drive Quality of Life Scores in Cushing’s Patients, Study Suggests

News

After adjusting for remission rates, patients with Cushing’s syndrome were found to have similar health-related quality of life (HRQoL) scores at long-term follow-up, regardless of whether the disease originated in ... Read more

April 19, 2018

Japan Endocrine Society Proposes Revised Diagnostic Criteria for Adrenal Subclinical Cushing’s Syndrome

News

The Japan Endocrine Society (JES) has proposed new criteria, including reviewed cutoff values for blood cortisol levels, for the diagnosis of adrenal subclinical Cushing’s syndrome (SCS), a type of Cushing’s ... Read more

April 17, 2018

Phase 2 Trial Testing Seliciclib for Cushing’s Disease Is Recruiting Participants

News

A new Phase 2 trial evaluating the promising investigative therapy seliciclib as a treatment for Cushing’s disease is currently enrolling participants. The trial (NCT02160730), at Cedars-Sinai Medical Center in Los Angeles, will ... Read more

April 13, 2018April 13, 2018

Fluorescent Metabolite Might Help Surgeons Remove Pituitary Tumors, Study Says

News

The resection of microadenomas — small, benign tumors in the pituitary gland underlying Cushing’s disease — could be aided by a fluorescent marker that is naturally produced by the ... Read more

April 13, 2018April 12, 2018

NIH Agency Pioneers Collaborative Research into Rare Diseases

News

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. ... Read more

April 12, 2018

Steroid Inhibitors in Cushing’s Led to Spontaneous Remission of Ectopic Tumors in Case Study

News

Inhibiting steroid production with metyrapone, a common therapy used in Cushing’s disease, may not only normalize cortisol levels but also lead to the spontaneous remission of ectopic tumors producing adrenocorticotropic hormone (ACTH), ... Read more

April 10, 2018April 10, 2018

Fluasterone Receives Orphan Drug Status for the Treatment of Hallmark Signs of Cushing’s Syndrome

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to fluasterone (ST-002) for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis, and high blood sugar in Cushing’s syndrome patients, SteroTherapeutics announced. ... Read more

April 6, 2018

Stronger MRI Enables Precise Spotting of Tumor Location in Cushing’s Disease Patients, Case Report Shows

News

Using magnetic resonance imaging (MRI) with superior magnetic strength enabled determination of precise tumor location in a patient with Cushing’s disease, a new case report describes. The research, “Value ... Read more

April 5, 2018

Strongbridge Starts Another Phase 3 Trial of Its Cushing’s Therapy

News

Strongbridge Biopharma has begun dosing patients in another Phase 3 clinical trial of its Cushing’s syndrome therapy Recorlev (levoketoconazole). The company will enroll roughly 35 patients in the LOGICS (NCT03277690). Those participating in ... Read more

April 3, 2018

Rare Nasal Cancer May Have Caused Cushing’s Syndrome, Case Report Says

News

A very rare case of Cushing’s syndrome developing as a result of a large and also rare cancer of the nasal sinuses gives insights into how to screen and treat ... Read more

Pin It on Pinterest